Lives unaffected by cystic fibrosis


Back to the Drug Development Pipeline

Gallium (Inhaled)

Phase One

Phase One

Therapeutic Approach


This program is studying an inhaled form of gallium. Gallium is a molecule, nearly identical to iron, that disrupts iron-dependent biological processes and has been shown to kill antibiotic-resistant strains of Pseudomonas aeruginosa in laboratory research. intravenous (IV) gallium has already been approved by the FDA for use in people and is now being studied for its safety and effectiveness in controlling P. aeruginosa in people with CF.


Laboratory studies to develop and test this compoud are underway.


This program is sponsored by Aridis Pharmaceuticals and partially funded by Cystic Fibrosis Foundation Therapeutics (CFFT).

Contact us about Gallium (Inhaled) >